News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CCBI Lifts CSPC PHARMA (01093.HK) TP to $6.5, Keeps Rating at Neutral
CSPC PHARMA (01093.HK)'s 1Q25 results bottomed out, with sales declining by 21.9% YoY to RMB7 billion, below the expected RMB7.26 billion, due to continued declines in sales of...
Reset
Send
The window will close in 5 seconds
<Research>CCBI Lifts CSPC PHARMA (01093.HK) TP to $6.5, Keeps Rating at Neutral
Close
Recommend
4
Positive
5
Negative
2
 
SHORT SELL
 
STOCK INFO

CSPC PHARMA (01093.HK)  +1.000 (+12.723%)    Short selling $780.41M; Ratio 19.653%   's 1Q25 results bottomed out, with sales declining by 21.9% YoY to RMB7 billion, below the expected RMB7.26 billion, due to continued declines in sales of neurological and oncology drugs, CCBI released a research report saying. Gross profit margin slipped by 1.1 ppt to 71.1%, 0.6 ppts lower than expected.

CCBI believed that CSPC PHARMA's worst period is over, and forecasted sales in core business segments to gradually improve in the coming quarters. Therefore, the broker kept rating at Neutral, and lifted its target price from $4.8 to $6.5.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-06 16:25.)

Related NewsHSBC Research Upgrades CSPC PHARMA to Buy, Raises TP to HKD9.5

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.